Cargando…

Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has spread all over the world resulting in high mortality, yet no specific antiviral treatment has been recommended. METHODS: A retrospective descriptive study was conducted involving 19 consecutive critically ill patients during January 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yonghao, Li, Manshu, Zhou, Liang, Liu, Dongdong, He, Weiqun, Liang, Weibo, Sun, Qingwen, Sun, Huadong, Li, Yimin, Liu, Xiaoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672023/
https://www.ncbi.nlm.nih.gov/pubmed/34916812
http://dx.doi.org/10.2147/IDR.S330743
_version_ 1784615273487138816
author Xu, Yonghao
Li, Manshu
Zhou, Liang
Liu, Dongdong
He, Weiqun
Liang, Weibo
Sun, Qingwen
Sun, Huadong
Li, Yimin
Liu, Xiaoqing
author_facet Xu, Yonghao
Li, Manshu
Zhou, Liang
Liu, Dongdong
He, Weiqun
Liang, Weibo
Sun, Qingwen
Sun, Huadong
Li, Yimin
Liu, Xiaoqing
author_sort Xu, Yonghao
collection PubMed
description BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has spread all over the world resulting in high mortality, yet no specific antiviral treatment has been recommended. METHODS: A retrospective descriptive study was conducted involving 19 consecutive critically ill patients during January 27, 2020 to April 18, 2020. Ribavirin was given at 0.15g q8h orally upon ICU admission for 7 to 21 days. Here, 28-day mortality, lower respiratory tract specimens (ETA), and ribavirin side effect on the day of ICU admission (Day 1), Day 7, Day 14 and Day 21 were analyzed. RESULTS: All the nineteen critically ill COVID-19 patients (14 males and 5 females, median age 56yr) survived through to the 28th day of observations with 6 patients (31.58%) being discharged from the ICU. The SARS-CoV-2 viral positivity in sputum/ETA was 100% (19/19) on Day 1, 73.68% (14/19) on Day 7, 57.89% (11/19) on Day 14 and 36.84% (7/19) on Day 21. Ribavirin side effect was not observed in these patients. CONCLUSION: Ribavirin is well tolerated in critically ill patients with COVID-19 and may benefit COVID-19 patients through increasing the virus clearance.
format Online
Article
Text
id pubmed-8672023
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86720232021-12-15 Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study Xu, Yonghao Li, Manshu Zhou, Liang Liu, Dongdong He, Weiqun Liang, Weibo Sun, Qingwen Sun, Huadong Li, Yimin Liu, Xiaoqing Infect Drug Resist Rapid Communication BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has spread all over the world resulting in high mortality, yet no specific antiviral treatment has been recommended. METHODS: A retrospective descriptive study was conducted involving 19 consecutive critically ill patients during January 27, 2020 to April 18, 2020. Ribavirin was given at 0.15g q8h orally upon ICU admission for 7 to 21 days. Here, 28-day mortality, lower respiratory tract specimens (ETA), and ribavirin side effect on the day of ICU admission (Day 1), Day 7, Day 14 and Day 21 were analyzed. RESULTS: All the nineteen critically ill COVID-19 patients (14 males and 5 females, median age 56yr) survived through to the 28th day of observations with 6 patients (31.58%) being discharged from the ICU. The SARS-CoV-2 viral positivity in sputum/ETA was 100% (19/19) on Day 1, 73.68% (14/19) on Day 7, 57.89% (11/19) on Day 14 and 36.84% (7/19) on Day 21. Ribavirin side effect was not observed in these patients. CONCLUSION: Ribavirin is well tolerated in critically ill patients with COVID-19 and may benefit COVID-19 patients through increasing the virus clearance. Dove 2021-12-10 /pmc/articles/PMC8672023/ /pubmed/34916812 http://dx.doi.org/10.2147/IDR.S330743 Text en © 2021 Xu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Rapid Communication
Xu, Yonghao
Li, Manshu
Zhou, Liang
Liu, Dongdong
He, Weiqun
Liang, Weibo
Sun, Qingwen
Sun, Huadong
Li, Yimin
Liu, Xiaoqing
Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
title Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
title_full Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
title_fullStr Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
title_full_unstemmed Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
title_short Ribavirin Treatment for Critically Ill COVID-19 Patients: An Observational Study
title_sort ribavirin treatment for critically ill covid-19 patients: an observational study
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672023/
https://www.ncbi.nlm.nih.gov/pubmed/34916812
http://dx.doi.org/10.2147/IDR.S330743
work_keys_str_mv AT xuyonghao ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT limanshu ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT zhouliang ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT liudongdong ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT heweiqun ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT liangweibo ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT sunqingwen ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT sunhuadong ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT liyimin ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy
AT liuxiaoqing ribavirintreatmentforcriticallyillcovid19patientsanobservationalstudy